Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M8,358Revenue (TTM) $M47.6Net Margin (%)-910.4Altman Z-Score17.4
Enterprise Value $M7,820EPS (TTM) $-8.2Operating Margin %-876.5Piotroski F-Score5
P/E(ttm)--Beneish M-Score63.7Pre-tax Margin (%)-907.1Higher ROA y-yN
Price/Book16.310-y EBITDA Growth Rate %--Quick Ratio6.4Cash flow > EarningsY
Price/Sales1545-y EBITDA Growth Rate %-14.5Current Ratio6.6Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-72.4Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-110.7Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M53.9ROIC % (ttm)--Gross Margin Increase y-yY

Gurus Latest Trades with TSRO

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

TSRO is held by these investors:



TSRO: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Huber Martin H. Jr.SVP & Cheif Medical Officer 2017-04-03Sell829$153.020.5view
English Edward CV.P. of Finance & Admin. 2017-03-06Sell10,000$178.06-13.64view
PEARSON TIMOTHY RExec. VP, CFO 2017-03-02Sell1,447$177.61-13.42view
Oliveira OrlandoSVP & GM, International 2017-03-02Sell249$177.61-13.42view
Huber Martin H. Jr.Sr. VP, Chief Medical Officer 2017-03-02Sell1,428$177.61-13.42view
Hedley Mary LynnePresident & COO 2017-03-02Sell3,927$177.61-13.42view
Farmer Joseph LSr VP,Gen. Counsel & Secretary 2017-03-02Sell1,449$177.61-13.42view
English Edward CVP of Finance & Administration 2017-03-02Sell229$177.61-13.42view
Bogle Grant C.Sr VP,Chief Commercial Officer 2017-03-02Sell1,447$177.61-13.42view
Huber Martin H. Jr.SVP & Chief Medical Officer 2017-01-03Sell190$136.2612.86view

Press Releases about TSRO :

Quarterly/Annual Reports about TSRO:

News about TSRO:

Articles On GuruFocus.com
TESARO Partners With Clinigen to Initiate European Managed Access Program for Niraparib in Patients May 11 2017 
Perceptive and Edelmen's Next NASDAQ IPO Debutant May 04 2017 
TESARO Announces Submission of Investigational New Drug Application for Anti-LAG Antibody TSR-033 to May 01 2017 
TESARO Initiates Registrational Development Program for Anti-PD-1 Antibody TSR-042 Apr 27 2017 
TESARO Announces Approval of VARUBY® (Oral Rolapitant Tablets) by European Commission Apr 26 2017 
Tesaro Announces Participation in Two Investor Conferences Apr 25 2017 
TESARO to Announce First-Quarter 2017 Financial Results on May 9, 2017 Apr 25 2017 
TESARO Announces Availability of Zejula™ (Niraparib) for Patients With Recurrent Ovarian Cancer Apr 19 2017 
Tesaro Wins Awards for Clinical Development Team of the Year and Clinical Partnership of the Year Apr 07 2017 
TESARO Announces Expanded Development Program for Niraparib Focused on the Treatment of Front-Line M Mar 27 2017 

More From Other Websites
National Survey Shows Resource, Emotional and Support Needs of the Ovarian Cancer Community May 22 2017
Conference Spotlights Drug Giant Donnybrooks In Cancer Treatments May 18 2017
TESARO, Inc. – Value Analysis (NASDAQ:TSRO) : May 18, 2017 May 18 2017
Did AstraZeneca Rival Just Launch A Potential Blockbuster Drug? May 17 2017
TESARO, Inc. breached its 50 day moving average in a Bullish Manner : TSRO-US : May 17, 2017 May 17 2017
Edited Transcript of TSRO earnings conference call or presentation 9-May-17 8:15pm GMT May 16 2017
TESARO Partners With Clinigen to Initiate European Managed Access Program for Niraparib in Patients... May 11 2017
Tesaro reports 1Q loss May 09 2017
TESARO Announces First-Quarter 2017 Operating Results May 09 2017
Investor Network: TESARO, Inc. to Host Earnings Call May 09 2017
KITE Plunges, Take Sector With It May 08 2017
Neurocrine Biosciences’ new drug may cost patients more than $10,000 a month, twice as much as... May 01 2017
TESARO Announces Submission of Investigational New Drug Application for Anti-LAG Antibody TSR-033 to... May 01 2017
Drug Trials Heating Up In The Breast and Ovarian Cancer Treatment Space Apr 27 2017
TESARO Initiates Registrational Development Program for Anti-PD-1 Antibody TSR-042 Apr 27 2017
TESARO Announces Approval of VARUBY® (Oral Rolapitant Tablets) by European Commission Apr 26 2017
TESARO to Announce First-Quarter 2017 Financial Results on May 9, 2017 Apr 25 2017
Tesaro Announces Participation in Two Investor Conferences Apr 25 2017
Tesaro Inc Bulls Need a Reality Check Apr 25 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat